Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.54 |
| ▸ | MTOR | P42345 | 3/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17708298 | 0.90 | PIK3CA (0.60) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL17708297 | 0.90 | PIK3CA (0.60) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL17708300 | 0.90 | PIK3CA (0.52) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL17708296 | 0.86 | PIK3CA (0.63) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL17708290 | 0.86 | PIK3CA (0.73) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL15454303 | 0.79 | PIK3CA (0.61) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL30366836 | 0.79 | PIK3CA (0.62) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL26115714 | 0.77 | PIK3CA (0.77) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL16727866 | 0.77 | PIK3CA (0.60) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL29310624 | 0.75 | PIK3CA (0.65) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440981-B2 | Pyrrolo[2, 1-F] [1,2,4]triazine derivative and use thereof for treating tumors | PHARMABLOCK (NANJING) R&D CO. LTD (CN) | 2016-09-13 | — | — | US | disclosed |
| US-9440981-B2 | Pyrrolo[2, 1-F] [1,2,4]triazine derivative and use thereof for treating tumors | PHARMABLOCK (NANJING) R&D CO. LTD (CN) | 2016-09-13 | — | — | US | disclosed |
| US-20160115166-A1 | PYRROLO[2, 1-F] [1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF FOR TREATING TUMORS | PHARMABLOCK (NANJING) R&D CO. LTD. (CN) | 2016-04-28 | — | — | US | disclosed |
| US-20160115166-A1 | PYRROLO[2, 1-F] [1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF FOR TREATING TUMORS | PHARMABLOCK (NANJING) R&D CO. LTD. (CN) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115166-A1 | PYRROLO[2, 1-F] [1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF FOR TREATING TUMORS | GLS2, GTF2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PIK3CA 2172/4885PIK3R1 3962/4885PIK3CB 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.